🇺🇸 Intravenous Methylprednisolone in United States

8 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 2 reports (25%)
  2. Abdominal Distension — 1 report (12.5%)
  3. Blood Creatinine Increased — 1 report (12.5%)
  4. Cardiac Failure Congestive — 1 report (12.5%)
  5. Cardiomegaly — 1 report (12.5%)
  6. Dyspnoea Exertional — 1 report (12.5%)
  7. Hyperkalaemia — 1 report (12.5%)

Source database →

Intravenous Methylprednisolone in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Intravenous Methylprednisolone approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Intravenous Methylprednisolone in United States?

Berinstein, Jeffrey is the originator. The local marketing authorisation holder may differ — check the official source linked above.